{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T18:00:46Z","timestamp":1776794446229,"version":"3.51.2"},"reference-count":86,"publisher":"Bioscientifica","issue":"4","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"abstract":"<jats:p>\n                    Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors with variable metastatic potential across molecular clusters. While the homologous recombination deficiency (HRD) score has been established as a surrogate for HRD-related genomic instability to guide prognostic evaluation and therapeutic options in multiple solid tumors, its relevance in PPGLs remains unexplored. Here, data from 133 PPGL patients in the TCGA database were extracted to assess relationships between the HRD score and molecular clusters, metastasis, metastasis-free survival (MFS), and other clinical characteristics. Subsequently, a real-world cohort of 54 matched blood\u2013tumor pairs was subjected to whole-exome sequencing, with HRD scores calculated to confirm the prior observations. The median HRD score was 7.0 and 9.0 in the TCGA-PPGL dataset and the clinical cohort, respectively. In the TCGA dataset, an elevated HRD score significantly correlated with metanephrine secretion, C2 cluster, and metastasis. Multivariate analysis identified a higher HRD score as an independent risk factor for shorter MFS (HR = 1.33,\n                    <jats:italic>P<\/jats:italic>\n                    = 0.008). Patients with HRD scores \u2265 7 exhibited significantly shorter MFS (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.037), which was observed exclusively within the C1A cluster (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.007). Analyses of our clinical validation cohort corroborated this cluster-specific distribution and further revealed higher HRD scores in three temozolomide-treated PPGLs compared with those treatment-naive C1A tumors (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.043). In conclusion, despite exhibiting lower levels in C1A clusters, an elevated HRD score emerges as a promising indicator for refined metastatic risk stratification in PPGLs. Futhermore, the substantial increase in HRD score following temozolomide treatment provides a rationale for PARP inhibitor sequential or combination therapy in metastatic PPGLs.\n                  <\/jats:p>","DOI":"10.1530\/erc-25-0301","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:13:38Z","timestamp":1773861218000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["Clinical relevance of HRD score in pheochromocytomas and paragangliomas: molecular cluster distribution and prognostic implications"],"prefix":"10.1530","volume":"33","author":[{"given":"Yue","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of The People\u2019s Republic of China, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunying","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of The People\u2019s Republic of China, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of The People\u2019s Republic of China, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of The People\u2019s Republic of China, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-7540","authenticated-orcid":true,"given":"Anli","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of The People\u2019s Republic of China, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Endocr Pathol","first-page":"90","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete O","year":"2022","unstructured":"Mete O\n, \nAsa SL\n, \nGill AJ\n, et al.\n Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol 2022 33 90\u2013114. (https:\/\/doi.org\/10.1007\/s12022-022-09704-6)"},{"key":"bib2","series-title":"J Clin Endocrinol Metab","first-page":"2367","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-prono study): A European Network for the Study of Adrenal Tumors Retrospective Study","volume":"104","author":"Hescot S","year":"2019","unstructured":"Hescot S\n, \nCurras-Freixes M\n, \nDeutschbein T\n, et al.\n Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-prono study): A European Network for the Study of Adrenal Tumors Retrospective Study. J Clin Endocrinol Metab 2019 104 2367\u20132374. (https:\/\/doi.org\/10.1210\/jc.2018-01968)"},{"key":"bib3","series-title":"Endocr Rev","first-page":"199","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting S","year":"2022","unstructured":"N\u00f6lting S\n, \nBechmann N\n, \nTaieb D\n, et al.\n Personalized management of pheochromocytoma and paraganglioma. Endocr Rev 2022 43 199\u2013239. (https:\/\/doi.org\/10.1210\/endrev\/bnab019)"},{"key":"bib4","series-title":"N Engl J Med","first-page":"2012","article-title":"Belzutifan for advanced pheochromocytoma or paraganglioma","volume":"393","author":"Jimenez C","year":"2025","unstructured":"Jimenez C\n, \nAndreassen M\n, \nDurand A\n, et al.\n Belzutifan for advanced pheochromocytoma or paraganglioma. N Engl J Med 2025 393 2012\u20132022. (https:\/\/doi.org\/10.1056\/nejmoa2504964)"},{"key":"bib5","series-title":"Cancer Cell","first-page":"181","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein L","year":"2017","unstructured":"Fishbein L\n, \nLeshchiner I\n, \nWalter V\n, et al.\n Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 2017 31 181\u2013193. (https:\/\/doi.org\/10.1016\/j.ccell.2017.01.001)"},{"key":"bib6","series-title":"Hum Mol Genet","first-page":"3974","article-title":"Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma","volume":"20","author":"Burnichon N","year":"2011","unstructured":"Burnichon N\n, \nVescovo L\n, \nAmar L\n, et al.\n Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet 2011 20 3974\u20133985. (https:\/\/doi.org\/10.1093\/hmg\/ddr324)"},{"key":"bib7","series-title":"Mol Cel","first-page":"179","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia A","year":"2010","unstructured":"Ciccia A\n & \nElledge SJ\n\n. The DNA damage response: making it safe to play with knives. Mol Cel 2010 40 179\u2013204. (https:\/\/doi.org\/10.1016\/j.molcel.2010.09.019)"},{"key":"bib8","series-title":"Nat Commun","first-page":"5584","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen L","year":"2020","unstructured":"Nguyen L\n, \nMartens JWM\n, \nVan Hoeck A\n, et al.\n Pan-cancer landscape of homologous recombination deficiency. Nat Commun 2020 11 5584. (https:\/\/doi.org\/10.1038\/s41467-020-19406-4)"},{"key":"bib9","series-title":"N Engl J Med","first-page":"523","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson M","year":"2017","unstructured":"Robson M\n, \nIm SA\n, \nSenkus E\n, et al.\n Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017 377 523\u2013533. (https:\/\/doi.org\/10.1056\/nejmoa1706450)"},{"key":"bib10","series-title":"N Engl J Med","first-page":"317","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan T","year":"2019","unstructured":"Golan T\n, \nHammel P\n, \nReni M\n, et al.\n Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019 381 317\u2013327. (https:\/\/doi.org\/10.1056\/nejmoa1903387)"},{"key":"bib11","series-title":"Biomark Res","first-page":"9","article-title":"Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs","volume":"3","author":"Marquard AM","year":"2015","unstructured":"Marquard AM\n, \nEklund AC\n, \nJoshi T\n, et al.\n Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res 2015 3 9. (https:\/\/doi.org\/10.1186\/s40364-015-0033-4)"},{"key":"bib12","series-title":"Cell Rep","first-page":"239","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas","volume":"23","author":"Knijnenburg TA","year":"2018","unstructured":"Knijnenburg TA\n, \nWang L\n, \nZimmermann MT\n, et al.\n Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. Cell Rep 2018 23 239\u2013254.e6. (https:\/\/doi.org\/10.1016\/j.celrep.2018.03.076)"},{"key":"bib13","series-title":"Clin Cancer Res","first-page":"3764","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli ML","year":"2016","unstructured":"Telli ML\n, \nTimms KM\n, \nReid J\n, et al.\n Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 2016 22 3764\u20133773. (https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-2477)"},{"key":"bib14","series-title":"Clin Chem","first-page":"735","article-title":"Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines","volume":"51","author":"Eisenhofer G","year":"2005","unstructured":"Eisenhofer G\n, \nLenders JW\n, \nGoldstein DS\n, et al.\n Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem 2005 51 735\u2013744. (https:\/\/doi.org\/10.1373\/clinchem.2004.045484)"},{"key":"bib15","series-title":"Hum Mutat","first-page":"564","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"den Dunnen JT","year":"2016","unstructured":"den Dunnen JT\n, \nDalgleish R\n, \nMaglott DR\n, et al.\n HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat 2016 37 564\u2013569. (https:\/\/doi.org\/10.1002\/humu.22981)"},{"key":"bib16","series-title":"Front Endocrinol","article-title":"Mutational profile and potential molecular therapeutic targets of pheochromocytoma","volume":"13","author":"Ma X","year":"2022","unstructured":"Ma X\n, \nLing C\n, \nZhao M\n, et al.\n Mutational profile and potential molecular therapeutic targets of pheochromocytoma. Front Endocrinol 2022 13 921645. (https:\/\/doi.org\/10.3389\/fendo.2022.921645)"},{"key":"bib17","series-title":"NPJ Breast Cancer","first-page":"16","article-title":"Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer","volume":"4","author":"Sztupinszki Z","year":"2018","unstructured":"Sztupinszki Z\n, \nDiossy M\n, \nKrzystanek M\n, et al.\n Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer 2018 4 16. (https:\/\/doi.org\/10.1038\/s41523-018-0066-6)"},{"key":"bib18","series-title":"Breast Cancer Res","first-page":"475","article-title":"Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes","volume":"16","author":"Timms KM","year":"2014","unstructured":"Timms KM\n, \nAbkevich V\n, \nHughes E\n, et al.\n Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 2014 16 475. (https:\/\/doi.org\/10.1186\/s13058-014-0475-x)"},{"key":"bib19","series-title":"Cells","first-page":"673","article-title":"The distinct role of HIF-1\u03b1 and HIF-2\u03b1 in hypoxia and angiogenesis","volume":"14","author":"Bakleh MZ","year":"2025","unstructured":"Bakleh MZ\n & \nAl Haj Zen A\n\n. The distinct role of HIF-1\u03b1 and HIF-2\u03b1 in hypoxia and angiogenesis. Cells 2025 14 673. (https:\/\/doi.org\/10.3390\/cells14090673)"},{"key":"bib20","series-title":"Mod Pathol","first-page":"1185","article-title":"Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer","volume":"34","author":"Lotan TL","year":"2021","unstructured":"Lotan TL\n, \nKaur HB\n, \nSalles DC\n, et al.\n Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. Mod Pathol 2021 34 1185\u20131193. (https:\/\/doi.org\/10.1038\/s41379-020-00731-4)"},{"key":"bib21","series-title":"Nat Commun","first-page":"1122","article-title":"Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma","volume":"14","author":"Calsina B","year":"2023","unstructured":"Calsina B\n, \nPi\u00f1eiro-Y\u00e1\u00f1ez E\n, \nMart\u00ednez-Montes \u00c1M\n, et al.\n Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma. Nat Commun 2023 14 1122. (https:\/\/doi.org\/10.1038\/s41467-023-36769-6)"},{"key":"bib22","series-title":"Am J Med Genet","first-page":"277","article-title":"Adrenal tumors in BRCA1\/BRCA2 mutation carriers","volume":"98","author":"Barak F","year":"2001","unstructured":"Barak F\n, \nShiri-Svredlov R\n, \nBruchim-Bar Sade R\n, et al.\n Adrenal tumors in BRCA1\/BRCA2 mutation carriers. Am J Med Genet 2001 98 277\u2013279. (https:\/\/doi.org\/10.1002\/1096-8628(20010122)98:3<277::aid-ajmg1082>3.0.co;2-q)"},{"key":"bib23","series-title":"NPJ Precis Oncol","first-page":"110","article-title":"Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma","volume":"7","author":"Feng J","year":"2023","unstructured":"Feng J\n, \nLan Y\n, \nLiu F\n, et al.\n Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma. NPJ Precis Oncol 2023 7 110. (https:\/\/doi.org\/10.1038\/s41698-023-00465-x)"},{"key":"bib24","series-title":"JCO Precis Oncol","article-title":"Utility of homologous recombination deficiency biomarkers across cancer types","volume":"6","author":"Takamatsu S","year":"2022","unstructured":"Takamatsu S\n, \nBrown JB\n, \nYamaguchi K\n, et al\n. Utility of homologous recombination deficiency biomarkers across cancer types. JCO Precis Oncol 2022 6 e2200085. (https:\/\/doi.org\/10.1200\/PO.22.00085)"},{"key":"bib25","series-title":"J Pathol Clin Res","article-title":"Homologous recombination deficiency score is an independent prognostic factor in esophageal squamous cell carcinoma","volume":"10","author":"Wang Y","year":"2024","unstructured":"Wang Y\n, \nDing B\n, \nTao Y\n, et al.\n Homologous recombination deficiency score is an independent prognostic factor in esophageal squamous cell carcinoma. J Pathol Clin Res 2024 10 e70007. (https:\/\/doi.org\/10.1002\/2056-4538.70007)"},{"key":"bib26","series-title":"BMC Med","first-page":"237","article-title":"Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)","volume":"20","author":"Zhu S","year":"2022","unstructured":"Zhu S\n, \nZhao J\n, \nNie L\n, et al.\n Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P). BMC Med 2022 20 237. (https:\/\/doi.org\/10.1186\/s12916-022-02430-0)"},{"key":"bib27","series-title":"Oral Oncol","article-title":"A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients","volume":"128","author":"Chen Y","year":"2022","unstructured":"Chen Y\n, \nZheng X\n, \nLin J\n, et al.\n A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients. Oral Oncol 2022 128 105860. (https:\/\/doi.org\/10.1016\/j.oraloncology.2022.105860)"},{"key":"bib28","series-title":"Clin Cancer Res","first-page":"3423","article-title":"Targeting NAD(+)\/PARP DNA repair pathway as a novel therapeutic approach to SDHB-mutated cluster I pheochromocytoma and paraganglioma","volume":"24","author":"Pang Y","year":"2018","unstructured":"Pang Y\n, \nLu Y\n, \nCaisova V\n, et al.\n Targeting NAD(+)\/PARP DNA repair pathway as a novel therapeutic approach to SDHB-mutated cluster I pheochromocytoma and paraganglioma. Clin Cancer Res 2018 24 3423\u20133432. (https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-3406)"},{"key":"bib29","series-title":"Endocr Relat Cancer","article-title":"Role of GDH and PARP inhibitors as novel treatments for SDHB-deficient PPGLs","volume":"32","author":"Tabebi M","year":"2025","unstructured":"Tabebi M\n, \nAbdallah S\n, \nEl-Serafi A\n, et al.\n Role of GDH and PARP inhibitors as novel treatments for SDHB-deficient PPGLs. Endocr Relat Cancer 2025 32 e250173. (https:\/\/doi.org\/10.1530\/erc-25-0173)"},{"key":"bib30","series-title":"Cancer Res","first-page":"3480","article-title":"Loss of SDHB promotes dysregulated iron homeostasis, oxidative stress, and sensitivity to ascorbate","volume":"81","author":"Goncalves J","year":"2021","unstructured":"Goncalves J\n, \nMoog S\n, \nMorin A\n, et al.\n Loss of SDHB promotes dysregulated iron homeostasis, oxidative stress, and sensitivity to ascorbate. Cancer Res 2021 81 3480\u20133494. (https:\/\/doi.org\/10.1158\/0008-5472.can-20-2936)"},{"key":"bib31","series-title":"Clin Cancer Res","first-page":"3868","article-title":"Therapeutic targeting of SDHB-mutated pheochromocytoma\/paraganglioma with pharmacologic ascorbic acid","volume":"26","author":"Liu Y","year":"2020","unstructured":"Liu Y\n, \nPang Y\n, \nZhu B\n, et al.\n Therapeutic targeting of SDHB-mutated pheochromocytoma\/paraganglioma with pharmacologic ascorbic acid. Clin Cancer Res 2020 26 3868\u20133880. (https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-2335)"},{"key":"bib32","series-title":"Nat Genet","first-page":"1086","article-title":"Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair","volume":"50","author":"Sulkowski PL","year":"2018","unstructured":"Sulkowski PL\n, \nSundaram RK\n, \nOeck S\n, et al.\n Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. Nat Genet 2018 50 1086\u20131092. (https:\/\/doi.org\/10.1038\/s41588-018-0170-4)"},{"key":"bib33","series-title":"Hum Mol Genet","first-page":"3136","article-title":"3rd. Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma","volume":"16","author":"Smith EH","year":"2007","unstructured":"Smith EH\n, \nJanknecht R\n & \nMaher LJ\n\n. 3rd. Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum Mol Genet 2007 16 3136\u20133148. (https:\/\/doi.org\/10.1093\/hmg\/ddm275)"},{"key":"bib34","series-title":"Nature","first-page":"586","article-title":"Oncometabolites suppress DNA repair by disrupting local chromatin signalling","volume":"582","author":"Sulkowski PL","year":"2020","unstructured":"Sulkowski PL\n, \nOeck S\n, \nDow J\n, et al.\n Oncometabolites suppress DNA repair by disrupting local chromatin signalling. Nature 2020 582 586\u2013591. (https:\/\/doi.org\/10.1038\/s41586-020-2363-0)"},{"key":"bib35","series-title":"Cancer Lett","article-title":"Development of succinate dehydrogenase subunit B-deficient tumor models for preclinical immunotherapy testing","volume":"632","author":"Hadrava Vanova K","year":"2025","unstructured":"Hadrava Vanova K\n, \nUher O\n, \nKraus M\n, et al.\n Development of succinate dehydrogenase subunit B-deficient tumor models for preclinical immunotherapy testing. Cancer Lett 2025 632 217969. (https:\/\/doi.org\/10.1016\/j.canlet.2025.217969)"},{"key":"bib36","series-title":"Transl Oncol","article-title":"Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)","volume":"35","author":"Menzel M","year":"2023","unstructured":"Menzel M\n, \nEndris V\n, \nSchwab C\n, et al.\n Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD). Transl Oncol 2023 35 101706. (https:\/\/doi.org\/10.1016\/j.tranon.2023.101706)"},{"key":"bib37","series-title":"N Engl J Med","first-page":"2416","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard I","year":"2019","unstructured":"Ray-Coquard I\n, \nPautier P\n, \nPignata S\n, et al.\n Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019 381 2416\u20132428. (https:\/\/doi.org\/10.1056\/nejmoa1911361)"},{"key":"bib38","series-title":"Cancers","first-page":"946","article-title":"Modification of homologous recombination deficiency score threshold and association with long-term survival in epithelial ovarian cancer","volume":"13","author":"How JA","year":"2021","unstructured":"How JA\n, \nJazaeri AA\n, \nFellman B\n, et al.\n Modification of homologous recombination deficiency score threshold and association with long-term survival in epithelial ovarian cancer. Cancers 2021 13 946. (https:\/\/doi.org\/10.3390\/cancers13050946)"},{"key":"bib39","series-title":"J Natl Cancer Cent","first-page":"280","article-title":"Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors","volume":"4","author":"Zhao D","year":"2024","unstructured":"Zhao D\n, \nWang A\n, \nLi Y\n, et al.\n Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors. J Natl Cancer Cent 2024 4 280\u2013287. (https:\/\/doi.org\/10.1016\/j.jncc.2024.05.005)"},{"key":"bib40","series-title":"Nat Commun","first-page":"2632","article-title":"Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles","volume":"16","author":"Flynn A","year":"2025","unstructured":"Flynn A\n, \nPattison AD\n, \nBalachander S\n, et al.\n Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles. Nat Commun 2025 16 2632. (https:\/\/doi.org\/10.1038\/s41467-025-57595-y)"},{"key":"bib41","series-title":"Nat Rev Endocrinol","first-page":"168","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert consensus statement","volume":"20","author":"Ta\u00efeb D","year":"2024","unstructured":"Ta\u00efeb D\n, \nN\u00f6lting S\n, \nPerrier ND\n, et al.\n Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert consensus statement. Nat Rev Endocrinol 2024 20 168\u2013184. (https:\/\/doi.org\/10.1038\/s41574-023-00926-0)"},{"key":"bib42","series-title":"J Endocrinological Invest","first-page":"3039","article-title":"A novel strategy for predicting the efficacy of temozolomide treatment for metastatic pheochromocytomas\/paragangliomas","volume":"47","author":"Cui Y","year":"2024","unstructured":"Cui Y\n, \nGao Y\n, \nZhou Y\n, et al.\n A novel strategy for predicting the efficacy of temozolomide treatment for metastatic pheochromocytomas\/paragangliomas. J Endocrinological Invest 2024 47 3039\u20133048. (https:\/\/doi.org\/10.1007\/s40618-024-02398-z)"},{"key":"bib43","series-title":"Endocr Relat Cancer","first-page":"375","article-title":"Preclinical evaluation of targeted therapies in Sdhb-mutated tumors","volume":"29","author":"Moog S","year":"2022","unstructured":"Moog S\n, \nSalgues B\n, \nBraik-Djellas Y\n, et al.\n Preclinical evaluation of targeted therapies in Sdhb-mutated tumors. Endocr Relat Cancer 2022 29 375\u2013388. (https:\/\/doi.org\/10.1530\/erc-22-0030)"},{"key":"bib1","series-title":"Endocr Pathol","first-page":"90","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete O","year":"2022","unstructured":"Mete O\n, \nAsa SL\n, \nGill AJ\n, et al.\n Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol 2022 33 90\u2013114. (https:\/\/doi.org\/10.1007\/s12022-022-09704-6)"},{"key":"bib2","series-title":"J Clin Endocrinol Metab","first-page":"2367","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-prono study): A European Network for the Study of Adrenal Tumors Retrospective Study","volume":"104","author":"Hescot S","year":"2019","unstructured":"Hescot S\n, \nCurras-Freixes M\n, \nDeutschbein T\n, et al.\n Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-prono study): A European Network for the Study of Adrenal Tumors Retrospective Study. J Clin Endocrinol Metab 2019 104 2367\u20132374. (https:\/\/doi.org\/10.1210\/jc.2018-01968)"},{"key":"bib3","series-title":"Endocr Rev","first-page":"199","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting S","year":"2022","unstructured":"N\u00f6lting S\n, \nBechmann N\n, \nTaieb D\n, et al.\n Personalized management of pheochromocytoma and paraganglioma. Endocr Rev 2022 43 199\u2013239. (https:\/\/doi.org\/10.1210\/endrev\/bnab019)"},{"key":"bib4","series-title":"N Engl J Med","first-page":"2012","article-title":"Belzutifan for advanced pheochromocytoma or paraganglioma","volume":"393","author":"Jimenez C","year":"2025","unstructured":"Jimenez C\n, \nAndreassen M\n, \nDurand A\n, et al.\n Belzutifan for advanced pheochromocytoma or paraganglioma. N Engl J Med 2025 393 2012\u20132022. (https:\/\/doi.org\/10.1056\/nejmoa2504964)"},{"key":"bib5","series-title":"Cancer Cell","first-page":"181","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein L","year":"2017","unstructured":"Fishbein L\n, \nLeshchiner I\n, \nWalter V\n, et al.\n Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 2017 31 181\u2013193. (https:\/\/doi.org\/10.1016\/j.ccell.2017.01.001)"},{"key":"bib6","series-title":"Hum Mol Genet","first-page":"3974","article-title":"Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma","volume":"20","author":"Burnichon N","year":"2011","unstructured":"Burnichon N\n, \nVescovo L\n, \nAmar L\n, et al.\n Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet 2011 20 3974\u20133985. (https:\/\/doi.org\/10.1093\/hmg\/ddr324)"},{"key":"bib7","series-title":"Mol Cel","first-page":"179","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia A","year":"2010","unstructured":"Ciccia A\n & \nElledge SJ\n\n. The DNA damage response: making it safe to play with knives. Mol Cel 2010 40 179\u2013204. (https:\/\/doi.org\/10.1016\/j.molcel.2010.09.019)"},{"key":"bib8","series-title":"Nat Commun","first-page":"5584","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen L","year":"2020","unstructured":"Nguyen L\n, \nMartens JWM\n, \nVan Hoeck A\n, et al.\n Pan-cancer landscape of homologous recombination deficiency. Nat Commun 2020 11 5584. (https:\/\/doi.org\/10.1038\/s41467-020-19406-4)"},{"key":"bib9","series-title":"N Engl J Med","first-page":"523","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson M","year":"2017","unstructured":"Robson M\n, \nIm SA\n, \nSenkus E\n, et al.\n Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017 377 523\u2013533. (https:\/\/doi.org\/10.1056\/nejmoa1706450)"},{"key":"bib10","series-title":"N Engl J Med","first-page":"317","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan T","year":"2019","unstructured":"Golan T\n, \nHammel P\n, \nReni M\n, et al.\n Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019 381 317\u2013327. (https:\/\/doi.org\/10.1056\/nejmoa1903387)"},{"key":"bib11","series-title":"Biomark Res","first-page":"9","article-title":"Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs","volume":"3","author":"Marquard AM","year":"2015","unstructured":"Marquard AM\n, \nEklund AC\n, \nJoshi T\n, et al.\n Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res 2015 3 9. (https:\/\/doi.org\/10.1186\/s40364-015-0033-4)"},{"key":"bib12","series-title":"Cell Rep","first-page":"239","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas","volume":"23","author":"Knijnenburg TA","year":"2018","unstructured":"Knijnenburg TA\n, \nWang L\n, \nZimmermann MT\n, et al.\n Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. Cell Rep 2018 23 239\u2013254.e6. (https:\/\/doi.org\/10.1016\/j.celrep.2018.03.076)"},{"key":"bib13","series-title":"Clin Cancer Res","first-page":"3764","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli ML","year":"2016","unstructured":"Telli ML\n, \nTimms KM\n, \nReid J\n, et al.\n Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 2016 22 3764\u20133773. (https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-2477)"},{"key":"bib14","series-title":"Clin Chem","first-page":"735","article-title":"Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines","volume":"51","author":"Eisenhofer G","year":"2005","unstructured":"Eisenhofer G\n, \nLenders JW\n, \nGoldstein DS\n, et al.\n Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem 2005 51 735\u2013744. (https:\/\/doi.org\/10.1373\/clinchem.2004.045484)"},{"key":"bib15","series-title":"Hum Mutat","first-page":"564","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"den Dunnen JT","year":"2016","unstructured":"den Dunnen JT\n, \nDalgleish R\n, \nMaglott DR\n, et al.\n HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat 2016 37 564\u2013569. (https:\/\/doi.org\/10.1002\/humu.22981)"},{"key":"bib16","series-title":"Front Endocrinol","article-title":"Mutational profile and potential molecular therapeutic targets of pheochromocytoma","volume":"13","author":"Ma X","year":"2022","unstructured":"Ma X\n, \nLing C\n, \nZhao M\n, et al.\n Mutational profile and potential molecular therapeutic targets of pheochromocytoma. Front Endocrinol 2022 13 921645. (https:\/\/doi.org\/10.3389\/fendo.2022.921645)"},{"key":"bib17","series-title":"NPJ Breast Cancer","first-page":"16","article-title":"Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer","volume":"4","author":"Sztupinszki Z","year":"2018","unstructured":"Sztupinszki Z\n, \nDiossy M\n, \nKrzystanek M\n, et al.\n Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer 2018 4 16. (https:\/\/doi.org\/10.1038\/s41523-018-0066-6)"},{"key":"bib18","series-title":"Breast Cancer Res","first-page":"475","article-title":"Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes","volume":"16","author":"Timms KM","year":"2014","unstructured":"Timms KM\n, \nAbkevich V\n, \nHughes E\n, et al.\n Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 2014 16 475. (https:\/\/doi.org\/10.1186\/s13058-014-0475-x)"},{"key":"bib19","series-title":"Cells","first-page":"673","article-title":"The distinct role of HIF-1\u03b1 and HIF-2\u03b1 in hypoxia and angiogenesis","volume":"14","author":"Bakleh MZ","year":"2025","unstructured":"Bakleh MZ\n & \nAl Haj Zen A\n\n. The distinct role of HIF-1\u03b1 and HIF-2\u03b1 in hypoxia and angiogenesis. Cells 2025 14 673. (https:\/\/doi.org\/10.3390\/cells14090673)"},{"key":"bib20","series-title":"Mod Pathol","first-page":"1185","article-title":"Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer","volume":"34","author":"Lotan TL","year":"2021","unstructured":"Lotan TL\n, \nKaur HB\n, \nSalles DC\n, et al.\n Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. Mod Pathol 2021 34 1185\u20131193. (https:\/\/doi.org\/10.1038\/s41379-020-00731-4)"},{"key":"bib21","series-title":"Nat Commun","first-page":"1122","article-title":"Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma","volume":"14","author":"Calsina B","year":"2023","unstructured":"Calsina B\n, \nPi\u00f1eiro-Y\u00e1\u00f1ez E\n, \nMart\u00ednez-Montes \u00c1M\n, et al.\n Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma. Nat Commun 2023 14 1122. (https:\/\/doi.org\/10.1038\/s41467-023-36769-6)"},{"key":"bib22","series-title":"Am J Med Genet","first-page":"277","article-title":"Adrenal tumors in BRCA1\/BRCA2 mutation carriers","volume":"98","author":"Barak F","year":"2001","unstructured":"Barak F\n, \nShiri-Svredlov R\n, \nBruchim-Bar Sade R\n, et al.\n Adrenal tumors in BRCA1\/BRCA2 mutation carriers. Am J Med Genet 2001 98 277\u2013279. (https:\/\/doi.org\/10.1002\/1096-8628(20010122)98:3<277::aid-ajmg1082>3.0.co;2-q)"},{"key":"bib23","series-title":"NPJ Precis Oncol","first-page":"110","article-title":"Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma","volume":"7","author":"Feng J","year":"2023","unstructured":"Feng J\n, \nLan Y\n, \nLiu F\n, et al.\n Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma. NPJ Precis Oncol 2023 7 110. (https:\/\/doi.org\/10.1038\/s41698-023-00465-x)"},{"key":"bib24","series-title":"JCO Precis Oncol","article-title":"Utility of homologous recombination deficiency biomarkers across cancer types","volume":"6","author":"Takamatsu S","year":"2022","unstructured":"Takamatsu S\n, \nBrown JB\n, \nYamaguchi K\n, et al\n. Utility of homologous recombination deficiency biomarkers across cancer types. JCO Precis Oncol 2022 6 e2200085. (https:\/\/doi.org\/10.1200\/PO.22.00085)"},{"key":"bib25","series-title":"J Pathol Clin Res","article-title":"Homologous recombination deficiency score is an independent prognostic factor in esophageal squamous cell carcinoma","volume":"10","author":"Wang Y","year":"2024","unstructured":"Wang Y\n, \nDing B\n, \nTao Y\n, et al.\n Homologous recombination deficiency score is an independent prognostic factor in esophageal squamous cell carcinoma. J Pathol Clin Res 2024 10 e70007. (https:\/\/doi.org\/10.1002\/2056-4538.70007)"},{"key":"bib26","series-title":"BMC Med","first-page":"237","article-title":"Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)","volume":"20","author":"Zhu S","year":"2022","unstructured":"Zhu S\n, \nZhao J\n, \nNie L\n, et al.\n Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P). BMC Med 2022 20 237. (https:\/\/doi.org\/10.1186\/s12916-022-02430-0)"},{"key":"bib27","series-title":"Oral Oncol","article-title":"A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients","volume":"128","author":"Chen Y","year":"2022","unstructured":"Chen Y\n, \nZheng X\n, \nLin J\n, et al.\n A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients. Oral Oncol 2022 128 105860. (https:\/\/doi.org\/10.1016\/j.oraloncology.2022.105860)"},{"key":"bib28","series-title":"Clin Cancer Res","first-page":"3423","article-title":"Targeting NAD(+)\/PARP DNA repair pathway as a novel therapeutic approach to SDHB-mutated cluster I pheochromocytoma and paraganglioma","volume":"24","author":"Pang Y","year":"2018","unstructured":"Pang Y\n, \nLu Y\n, \nCaisova V\n, et al.\n Targeting NAD(+)\/PARP DNA repair pathway as a novel therapeutic approach to SDHB-mutated cluster I pheochromocytoma and paraganglioma. Clin Cancer Res 2018 24 3423\u20133432. (https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-3406)"},{"key":"bib29","series-title":"Endocr Relat Cancer","article-title":"Role of GDH and PARP inhibitors as novel treatments for SDHB-deficient PPGLs","volume":"32","author":"Tabebi M","year":"2025","unstructured":"Tabebi M\n, \nAbdallah S\n, \nEl-Serafi A\n, et al.\n Role of GDH and PARP inhibitors as novel treatments for SDHB-deficient PPGLs. Endocr Relat Cancer 2025 32 e250173. (https:\/\/doi.org\/10.1530\/erc-25-0173)"},{"key":"bib30","series-title":"Cancer Res","first-page":"3480","article-title":"Loss of SDHB promotes dysregulated iron homeostasis, oxidative stress, and sensitivity to ascorbate","volume":"81","author":"Goncalves J","year":"2021","unstructured":"Goncalves J\n, \nMoog S\n, \nMorin A\n, et al.\n Loss of SDHB promotes dysregulated iron homeostasis, oxidative stress, and sensitivity to ascorbate. Cancer Res 2021 81 3480\u20133494. (https:\/\/doi.org\/10.1158\/0008-5472.can-20-2936)"},{"key":"bib31","series-title":"Clin Cancer Res","first-page":"3868","article-title":"Therapeutic targeting of SDHB-mutated pheochromocytoma\/paraganglioma with pharmacologic ascorbic acid","volume":"26","author":"Liu Y","year":"2020","unstructured":"Liu Y\n, \nPang Y\n, \nZhu B\n, et al.\n Therapeutic targeting of SDHB-mutated pheochromocytoma\/paraganglioma with pharmacologic ascorbic acid. Clin Cancer Res 2020 26 3868\u20133880. (https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-2335)"},{"key":"bib32","series-title":"Nat Genet","first-page":"1086","article-title":"Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair","volume":"50","author":"Sulkowski PL","year":"2018","unstructured":"Sulkowski PL\n, \nSundaram RK\n, \nOeck S\n, et al.\n Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. Nat Genet 2018 50 1086\u20131092. (https:\/\/doi.org\/10.1038\/s41588-018-0170-4)"},{"key":"bib33","series-title":"Hum Mol Genet","first-page":"3136","article-title":"3rd. Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma","volume":"16","author":"Smith EH","year":"2007","unstructured":"Smith EH\n, \nJanknecht R\n & \nMaher LJ\n\n. 3rd. Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum Mol Genet 2007 16 3136\u20133148. (https:\/\/doi.org\/10.1093\/hmg\/ddm275)"},{"key":"bib34","series-title":"Nature","first-page":"586","article-title":"Oncometabolites suppress DNA repair by disrupting local chromatin signalling","volume":"582","author":"Sulkowski PL","year":"2020","unstructured":"Sulkowski PL\n, \nOeck S\n, \nDow J\n, et al.\n Oncometabolites suppress DNA repair by disrupting local chromatin signalling. Nature 2020 582 586\u2013591. (https:\/\/doi.org\/10.1038\/s41586-020-2363-0)"},{"key":"bib35","series-title":"Cancer Lett","article-title":"Development of succinate dehydrogenase subunit B-deficient tumor models for preclinical immunotherapy testing","volume":"632","author":"Hadrava Vanova K","year":"2025","unstructured":"Hadrava Vanova K\n, \nUher O\n, \nKraus M\n, et al.\n Development of succinate dehydrogenase subunit B-deficient tumor models for preclinical immunotherapy testing. Cancer Lett 2025 632 217969. (https:\/\/doi.org\/10.1016\/j.canlet.2025.217969)"},{"key":"bib36","series-title":"Transl Oncol","article-title":"Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)","volume":"35","author":"Menzel M","year":"2023","unstructured":"Menzel M\n, \nEndris V\n, \nSchwab C\n, et al.\n Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD). Transl Oncol 2023 35 101706. (https:\/\/doi.org\/10.1016\/j.tranon.2023.101706)"},{"key":"bib37","series-title":"N Engl J Med","first-page":"2416","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard I","year":"2019","unstructured":"Ray-Coquard I\n, \nPautier P\n, \nPignata S\n, et al.\n Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019 381 2416\u20132428. (https:\/\/doi.org\/10.1056\/nejmoa1911361)"},{"key":"bib38","series-title":"Cancers","first-page":"946","article-title":"Modification of homologous recombination deficiency score threshold and association with long-term survival in epithelial ovarian cancer","volume":"13","author":"How JA","year":"2021","unstructured":"How JA\n, \nJazaeri AA\n, \nFellman B\n, et al.\n Modification of homologous recombination deficiency score threshold and association with long-term survival in epithelial ovarian cancer. Cancers 2021 13 946. (https:\/\/doi.org\/10.3390\/cancers13050946)"},{"key":"bib39","series-title":"J Natl Cancer Cent","first-page":"280","article-title":"Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors","volume":"4","author":"Zhao D","year":"2024","unstructured":"Zhao D\n, \nWang A\n, \nLi Y\n, et al.\n Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors. J Natl Cancer Cent 2024 4 280\u2013287. (https:\/\/doi.org\/10.1016\/j.jncc.2024.05.005)"},{"key":"bib40","series-title":"Nat Commun","first-page":"2632","article-title":"Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles","volume":"16","author":"Flynn A","year":"2025","unstructured":"Flynn A\n, \nPattison AD\n, \nBalachander S\n, et al.\n Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles. Nat Commun 2025 16 2632. (https:\/\/doi.org\/10.1038\/s41467-025-57595-y)"},{"key":"bib41","series-title":"Nat Rev Endocrinol","first-page":"168","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert consensus statement","volume":"20","author":"Ta\u00efeb D","year":"2024","unstructured":"Ta\u00efeb D\n, \nN\u00f6lting S\n, \nPerrier ND\n, et al.\n Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert consensus statement. Nat Rev Endocrinol 2024 20 168\u2013184. (https:\/\/doi.org\/10.1038\/s41574-023-00926-0)"},{"key":"bib42","series-title":"J Endocrinological Invest","first-page":"3039","article-title":"A novel strategy for predicting the efficacy of temozolomide treatment for metastatic pheochromocytomas\/paragangliomas","volume":"47","author":"Cui Y","year":"2024","unstructured":"Cui Y\n, \nGao Y\n, \nZhou Y\n, et al.\n A novel strategy for predicting the efficacy of temozolomide treatment for metastatic pheochromocytomas\/paragangliomas. J Endocrinological Invest 2024 47 3039\u20133048. (https:\/\/doi.org\/10.1007\/s40618-024-02398-z)"},{"key":"bib43","series-title":"Endocr Relat Cancer","first-page":"375","article-title":"Preclinical evaluation of targeted therapies in Sdhb-mutated tumors","volume":"29","author":"Moog S","year":"2022","unstructured":"Moog S\n, \nSalgues B\n, \nBraik-Djellas Y\n, et al.\n Preclinical evaluation of targeted therapies in Sdhb-mutated tumors. Endocr Relat Cancer 2022 29 375\u2013388. (https:\/\/doi.org\/10.1530\/erc-22-0030)"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/33\/4\/ERC-25-0301.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/33\/4\/ERC-25-0301.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/33\/4\/ERC-25-0301.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:00:24Z","timestamp":1776790824000},"score":1,"resource":{"primary":{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/33\/4\/ERC-25-0301.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":86,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0301","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}